Shares of Amarin (AMRN -2.2%) slip out of the gate this morning, possibly on cautious comments out of Summer Street. The firm says Vascepa doesn't have data to support superiority compared to other fish oils such as Lovaza by Glaxo SmithKline (GSK -0.6%) which third party payers are likely to favor. [View news story]
AMRN slips because the whole market is down today, not because of the cautious comments or any other bs. Stocks may be manipulated, but smart investors dont dump stocks just because of random news.
Amarin (AMRN +5%) trades up after being awarded a patent for its fish oil pill Vascepa. Citigroup plays catch-up with the rest of the Street by initiating the shares with a Buy and a $20 price target on the news. Citi says that concerns over an exclusivity decision on the pill had put pressure on the stock and driven valuations near a "worst case" scenario, but that overhang has now been removed and the risk/reward is favorable. The firm adds that Vascepa has a near $1B commercial potential, even if AMRN has to launch the drug alone. [View news story]
What if I bought on dips because I've seen the potential in this stock, and want to stock more shares? This is what I believe in: [...] to be fearful when others are greedy and greedy when others are fearful - Warren Buffet.
ImmunoCellular Therapeutics (IMUC) +19.3% premarket as Maxim Group begins coverage with a Buy rating and an $18 price target. The firm says IMUC has the potential to create a new, innovative second-generation dendritic cancer vaccine to address perceived shortfalls of Dendreon's (DNDN) Provenge. If successful, the firm thinks it could become a billion-dollar product. [View news story]
Market, market, market! Who did not hear IMUC was working on billion-dollar product before it took a nose-dive last month? Great move to cover loss big boys!
3 Speculative Biotech Stocks To Electrify Your Boring Portfolio [View article]
The more I'm enthusiastic about ACTC's management team, the less I'm about its total number of outstanding shares: 2.1B shares as of Sep 3rd, 2012. After rounds of stock dilution (which I think is inevitable for a small cap company like ACTC), I'm not quite sure about the prospect of this company. Just my 2 cents!
In Defense Of Apple: Battling The Mounting Hysteria [View article]
Shares of Amarin (AMRN -2.2%) slip out of the gate this morning, possibly on cautious comments out of Summer Street. The firm says Vascepa doesn't have data to support superiority compared to other fish oils such as Lovaza by Glaxo SmithKline (GSK -0.6%) which third party payers are likely to favor. [View news story]
Amarin (AMRN +5%) trades up after being awarded a patent for its fish oil pill Vascepa. Citigroup plays catch-up with the rest of the Street by initiating the shares with a Buy and a $20 price target on the news. Citi says that concerns over an exclusivity decision on the pill had put pressure on the stock and driven valuations near a "worst case" scenario, but that overhang has now been removed and the risk/reward is favorable. The firm adds that Vascepa has a near $1B commercial potential, even if AMRN has to launch the drug alone. [View news story]
The Other Side Of Galena Biopharma [View article]
The Other Side Of Galena Biopharma [View article]
Navidea Biopharmaceuticals Resubmits New Drug Application for Lymphoseek® to FDA [View article]
3 Pharmaceuticals Pursuing Non-Surgical Approaches To Combating Cancer [View article]
Apple: One More Thing [View article]
Apple: One More Thing [View article]
Diverse Pipeline And Multiple Catalysts Point To Buying Opportunity In NovaBay Pharmaceuticals [View article]
ImmunoCellular Therapeutics (IMUC) +19.3% premarket as Maxim Group begins coverage with a Buy rating and an $18 price target. The firm says IMUC has the potential to create a new, innovative second-generation dendritic cancer vaccine to address perceived shortfalls of Dendreon's (DNDN) Provenge. If successful, the firm thinks it could become a billion-dollar product. [View news story]
Earnings Preview: Accuray Incorporated Reports On September 6 [View article]
3 Speculative Biotech Stocks To Electrify Your Boring Portfolio [View article]